Neoleukin Therapeutics (NASDAQ:NLTX) Stock Price Down 1.1% - Here's What Happened

Key Points

• Neoleukin Therapeutics (NASDAQ:NLTX) experienced a stock price decline of 1.1%, trading between $33.06 and $33.99 on Friday.
• Trading volume surged to approximately 284,768 shares, significantly higher than its daily average of 50,104 shares.
• The company focuses on developing immunotherapies for cancer using unique protein design technology, with its lead candidate NL-201 aimed at treating various cancers.

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - ) was down 1.1% on Friday . The company traded as low as $33.06 and last traded at $33.99. Approximately 284,768 shares traded hands during trading, an increase of 468% from the average daily volume of 50,104 shares. The stock had previously closed at $34.37.

Neoleukin Therapeutics Price Performance

The firm's fifty day moving average is $21.02 and its two-hundred day moving average is $18.55. The firm has a market cap of $319.44 million, a price-to-earnings ratio of -10.93 and a beta of 1.11.

About Neoleukin Therapeutics

Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.